These studies suggest that IPF fibroblasts utilize CCR7 and CCL21 for migration, survival, proliferation and activation, in a similar manner as many cancer cells, and that targeting this chemokine and its receptor therapeutically might ameliorate IPF. Here, CCR7 is linked to idiopathic pulmonary fibrosis.